Van ECK Associates Corp increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 128,050 shares of the biopharmaceutical company’s stock after buying an additional 25,273 shares during the period. Van ECK Associates Corp owned 0.15% of Alnylam Pharmaceuticals worth $10,213,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. CIBC Asset Management Inc purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $221,000. Neuberger Berman Group LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $229,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Alnylam Pharmaceuticals in the 1st quarter worth about $148,000. Capstone Asset Management Co. purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $232,000. Finally, Hemenway Trust Co LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $235,000. 94.25% of the stock is currently owned by institutional investors.

Shares of Alnylam Pharmaceuticals, Inc. (ALNY) opened at 113.80 on Friday. The company’s market capitalization is $10.44 billion. Alnylam Pharmaceuticals, Inc. has a 12-month low of $31.38 and a 12-month high of $118.40. The stock has a 50 day moving average of $81.14 and a 200-day moving average of $69.12. Alnylam Pharmaceuticals also saw unusually large options trading activity on Wednesday. Stock investors purchased 30,530 call options on the company. This represents an increase of 937% compared to the typical daily volume of 2,944 call options.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). The business had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm’s revenue for the quarter was up 82.9% on a year-over-year basis. During the same quarter last year, the company earned ($1.05) earnings per share. Analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.19) earnings per share for the current fiscal year.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of the business’s stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the sale, the president now directly owns 165,399 shares in the company, valued at $16,539,900. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.30% of the stock is owned by corporate insiders.

A number of research firms have commented on ALNY. Zacks Investment Research raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $88.00 target price on the stock in a research report on Wednesday, July 12th. Needham & Company LLC reissued a “buy” rating and set a $85.00 target price (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. BMO Capital Markets reissued an “outperform” rating and set a $99.00 target price (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. ValuEngine downgraded shares of Alnylam Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 27th. Finally, Credit Suisse Group raised their target price on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the company an “outperform” rating in a research report on Tuesday, June 27th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Hold” and an average price target of $93.11.

ILLEGAL ACTIVITY WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Position Lifted by Van ECK Associates Corp” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/23/alnylam-pharmaceuticals-inc-alny-position-lifted-by-van-eck-associates-corp.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.